Novartis heart failure drug cuts death by 37 percent: study
LOS ANGELES (Reuters) - An experimental Novartis AG drug to treat hospitalized acute heart failure patients reduced deaths by 37 percent compared with a placebo and appeared to be safe, according to data from a late stage clinical trial presented on ...
Novartis' heart failure drug faces hurdles despite upbeat PhIII results
Pregnancy Hormone Shows Promise as Heart Failure Drug
RELAX-AHF Stirs Interest In Novel Drug For Acute Heart Failure